SCHEMBL3610099

SCHEMBL3610099

COC(=O)c1cc(O)cc(Oc2ccc(SC(C)C)cc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.49
CA2 P00918 5/20 0.49
CA12 O43570 4/20 0.49
CA7 P43166 4/20 0.49
CA9 Q16790 4/20 0.49
CA14 Q9ULX7 4/20 0.49
USP2 O75604 1/20 0.40
MMP2 P08253 1/20 0.37
ADAM17 P78536 1/20 0.37
LMNA P02545 5/20 0.37
XDH P47989 2/20 0.37
KDM4E B2RXH2 2/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
NFKB1 P19838 1/20 0.37
GFER P55789 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
FUT7 Q11130 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3599023 0.85 CA1 (0.53) CA1CA2CA12CA7CA9
SCHEMBL3609653 0.83 MAPT (0.38) CA1CA2USP2MMP2ADAM17
SCHEMBL3604657 0.82 CA1 (0.49) CA1CA2CA12CA7CA9
SCHEMBL2656111 0.79 CA1 (0.56) CA1CA2CA12CA7CA9
SCHEMBL12487336 0.79 CA1 (0.56) CA1CA2CA12CA7CA9
SCHEMBL3600119 0.79 MAPT (0.58) CA1CA2CA12CA7CA9
SCHEMBL710275 0.79 CA12 (0.59) CA1CA2CA12CA7CA9
SCHEMBL2086052 0.77 CA12 (0.53) CA1CA2CA12CA7CA9
SCHEMBL6350638 0.77 CA1 (0.60) CA1CA2CA12CA7CA9
SCHEMBL4949461 0.76 CA1 (0.53) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1600442-B1 HETEROARYLCARBAMOYLBENZENE DERIVATIVE MSD KK (JP) 2018-01-17 EP disclosed
US-7754743-B2 Heteroarylcarbamoylbenzene derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-07-13 US disclosed
US-20090018056-A1 Heteroarylcarbamoylbenzene derivatives MSD K.K. (JP) 2009-01-15 US disclosed
US-7432287-B2 Heteroarylcarbamoylbenzene derivative BANYU PHARMECEUTICAL CO., LTD. (JP) 2008-10-07 US disclosed
US-20060167053-A1 Heteroarylcarbamoylbenzene derivative MSD K.K. (JP) 2006-07-27 US disclosed
EP-1600442-A1 HETEROARYLCARBAMOYLBENZENE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018056-A1 Heteroarylcarbamoylbenzene derivatives GCK, GCKR, KHK CA1 2194/4885CA2 593/4885CA12 2609/4885
US-20060167053-A1 Heteroarylcarbamoylbenzene derivative GCK, GCKR, GALK1 CA1 3859/4885CA2 1370/4885CA12 3515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.